FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034783640> ?p ?o ?g. }

• W2034783640 endingPage "64" @default.
• W2034783640 startingPage "59" @default.
• W2034783640 abstract "The toxicity and efficacy of nonpegylated liposomal doxorubicin (TLC D-99) when substituted for conventional doxorubicin in the CHOP (doxorubicin/cyclophosphamide/vincristine/prednisone) regimen were evaluated in the treatment of newly diagnosed patients with aggressive non-Hodgkin's lymphoma. Liposomal doxorubicin at doses of 40 mg/m2, 50 mg/m2, 60 mg/m2, and 80 mg/m2 was given with fixed doses of cyclophosphamide, vincristine, and prednisone. Chemotherapy cycles were repeated every 21 days. Forty-seven patients with a median age of 55 years (range, 25-83 years) were studied. No dose-limiting toxicities were observed at any level. Reversible grade 3/4 neutropenia was the most common toxicity (95.8%). Most nonhematologic side effects were grade 1/2 in severity. Complete remissions were documented in 31 of 46 evaluable patients (67.4%) and partial remissions in 7 (15.2%), for an overall major response rate of 82.6%. The median duration of complete remission is ≥ 27.7 months (range, 2.4 months to ≥ 59.8 months). An exploratory objective was to correlate multidrug resistance–1 (MDR-1) expression with outcome. Immunohistochemistry for MDR-1-related p-glycoprotein was assessed in lymphoma tissues from 27 patients. Of the 27 lymphoma tissues studied, 8 (30%) were MDR-1 positive at diagnosis. The complete response rate was 63% in MDR-1–positive lymphomas and 74% in the MDR-1–negative cases (P = 0.66). Nonpegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is an active regimen for patients with newly diagnosed, aggressive non-Hodgkin's lymphoma. The regimen is relatively well tolerated, with hematologic suppression as the major toxicity. Liposomal encapsulation might evade resistance caused by MDR-1 expression." @default.
• W2034783640 created "2016-06-24" @default.
• W2034783640 creator A5005358222 @default.
• W2034783640 creator A5024642865 @default.
• W2034783640 creator A5030671395 @default.
• W2034783640 creator A5044588619 @default.
• W2034783640 creator A5046826779 @default.
• W2034783640 creator A5047679990 @default.
• W2034783640 creator A5048430536 @default.
• W2034783640 creator A5051632521 @default.
• W2034783640 creator A5052181310 @default.
• W2034783640 creator A5060338136 @default.
• W2034783640 creator A5067821687 @default.
• W2034783640 creator A5082582380 @default.
• W2034783640 date "2006-07-01" @default.
• W2034783640 modified "2023-10-13" @default.
• W2034783640 title "Phase I/II Trial of Nonpegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma" @default.
• W2034783640 cites W1528514916 @default.
• W2034783640 cites W1776168062 @default.
• W2034783640 cites W1827669382 @default.
• W2034783640 cites W1911376378 @default.
• W2034783640 cites W2024075791 @default.
• W2034783640 cites W2058015212 @default.
• W2034783640 cites W2070739630 @default.
• W2034783640 cites W2103970111 @default.
• W2034783640 cites W2126232974 @default.
• W2034783640 cites W2141968482 @default.
• W2034783640 cites W2170776146 @default.
• W2034783640 cites W2227630971 @default.
• W2034783640 cites W2318772898 @default.
• W2034783640 cites W2587392921 @default.
• W2034783640 cites W4205736005 @default.
• W2034783640 doi "https://doi.org/10.3816/clm.2006.n.040" @default.
• W2034783640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16879771" @default.
• W2034783640 hasPublicationYear "2006" @default.
• W2034783640 type Work @default.
• W2034783640 sameAs 2034783640 @default.
• W2034783640 citedByCount "24" @default.
• W2034783640 countsByYear W20347836402013 @default.
• W2034783640 countsByYear W20347836402014 @default.
• W2034783640 countsByYear W20347836402015 @default.
• W2034783640 countsByYear W20347836402017 @default.
• W2034783640 countsByYear W20347836402019 @default.
• W2034783640 crossrefType "journal-article" @default.
• W2034783640 hasAuthorship W2034783640A5005358222 @default.
• W2034783640 hasAuthorship W2034783640A5024642865 @default.
• W2034783640 hasAuthorship W2034783640A5030671395 @default.
• W2034783640 hasAuthorship W2034783640A5044588619 @default.
• W2034783640 hasAuthorship W2034783640A5046826779 @default.
• W2034783640 hasAuthorship W2034783640A5047679990 @default.
• W2034783640 hasAuthorship W2034783640A5048430536 @default.
• W2034783640 hasAuthorship W2034783640A5051632521 @default.
• W2034783640 hasAuthorship W2034783640A5052181310 @default.
• W2034783640 hasAuthorship W2034783640A5060338136 @default.
• W2034783640 hasAuthorship W2034783640A5067821687 @default.
• W2034783640 hasAuthorship W2034783640A5082582380 @default.
• W2034783640 hasConcept C126322002 @default.
• W2034783640 hasConcept C141071460 @default.
• W2034783640 hasConcept C2776694085 @default.
• W2034783640 hasConcept C2776755627 @default.
• W2034783640 hasConcept C2778720950 @default.
• W2034783640 hasConcept C2779338263 @default.
• W2034783640 hasConcept C2779429289 @default.
• W2034783640 hasConcept C2779725641 @default.
• W2034783640 hasConcept C2780653079 @default.
• W2034783640 hasConcept C2781214270 @default.
• W2034783640 hasConcept C2781303535 @default.
• W2034783640 hasConcept C2781413609 @default.
• W2034783640 hasConcept C71924100 @default.
• W2034783640 hasConcept C90924648 @default.
• W2034783640 hasConceptScore W2034783640C126322002 @default.
• W2034783640 hasConceptScore W2034783640C141071460 @default.
• W2034783640 hasConceptScore W2034783640C2776694085 @default.
• W2034783640 hasConceptScore W2034783640C2776755627 @default.
• W2034783640 hasConceptScore W2034783640C2778720950 @default.
• W2034783640 hasConceptScore W2034783640C2779338263 @default.
• W2034783640 hasConceptScore W2034783640C2779429289 @default.
• W2034783640 hasConceptScore W2034783640C2779725641 @default.
• W2034783640 hasConceptScore W2034783640C2780653079 @default.
• W2034783640 hasConceptScore W2034783640C2781214270 @default.
• W2034783640 hasConceptScore W2034783640C2781303535 @default.
• W2034783640 hasConceptScore W2034783640C2781413609 @default.
• W2034783640 hasConceptScore W2034783640C71924100 @default.
• W2034783640 hasConceptScore W2034783640C90924648 @default.
• W2034783640 hasIssue "1" @default.
• W2034783640 hasLocation W20347836401 @default.
• W2034783640 hasLocation W20347836402 @default.
• W2034783640 hasOpenAccess W2034783640 @default.
• W2034783640 hasPrimaryLocation W20347836401 @default.
• W2034783640 hasRelatedWork W1896861650 @default.
• W2034783640 hasRelatedWork W1921119956 @default.
• W2034783640 hasRelatedWork W1986487042 @default.
• W2034783640 hasRelatedWork W2017046780 @default.
• W2034783640 hasRelatedWork W2031021461 @default.
• W2034783640 hasRelatedWork W2044362603 @default.
• W2034783640 hasRelatedWork W2047206303 @default.
• W2034783640 hasRelatedWork W2087824134 @default.
• W2034783640 hasRelatedWork W2138201596 @default.

• next